Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 19;24(1):219.
doi: 10.3892/ol.2022.13340. eCollection 2022 Jul.

Therapeutic pattern and progress of neoadjuvant treatment for triple-negative breast cancer

Yan Xiao  1 , Wencheng Gao  2
Affiliations
Review

Therapeutic pattern and progress of neoadjuvant treatment for triple-negative breast cancer

Yan Xiao et al. Oncol Lett. .

Abstract

Triple-negative breast cancer (TNBC) is a heterogeneous disease, accounting for about 15.0-20.0% of all breast cancer cases. TNBC is associated with early recurrence and metastasis, strong invasiveness and a poor prognosis. Chemotherapy is currently the mainstay of treatment for TNBC, and achievement of a pathological complete response is closely associated with a long-term good prognosis. Improving the long-term prognosis in patients with TNBC is a challenge in breast cancer treatment, and more clinical evidence is needed to guide the choice of treatment strategies. The current study reviews the conventional treatment modality for TNBC and the selection of neoadjuvant chemotherapy (NACT) regimens available. The research progress on optimizing NACT regimens is also reviewed, and the uniqueness of the treatment of this breast cancer subtype is emphasized, in order to provide reference for the clinical practice and research with regard to TNBC treatment.

Keywords: BRCA status; chemotherapy; homologous recombination deficiency score; immunotherapy; platinum agents; poly(ADP-ribose) polymerase-inhibitors; programmed cell death protein 1/programmed cell death 1 ligand 1 inhibitors; triple-negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Caglevic C, Anabalón J, Soza C, Milla E, Gaete F, Carrasco AM, Panay S, Gallardo C, Mahave M. Triple-negative breast cancer: The reality in Chile and in Latin America. Ecancermedicalscience. 2019;13:893. doi: 10.3332/ecancer.2019.893. - DOI - PMC - PubMed
    1. Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA, Jr, Ellis P, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol. 2012;30:1879–1887. doi: 10.1200/JCO.2011.38.2010. - DOI - PubMed
    1. Zhang J, Lin Y, Sun XJ, Wang BY, Wang ZH, Luo JF, Wang LP, Zhang S, Cao J, Tao ZH, et al. Biomarker assessment of the CBCSG006 trial: A randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Ann Oncol. 2018;29:1741–1747. doi: 10.1093/annonc/mdy209. - DOI - PubMed
    1. Leon-Ferre RA, Polley MY, Liu H, Gilbert JA, Cafourek V, Hillman DW, Elkhanany A, Akinhanmi M, Lilyquist J, Thomas A, et al. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat. 2018;167:89–99. doi: 10.1007/s10549-017-4499-7. - DOI - PMC - PubMed
    1. Chen H, Wu J, Zhang Z, Tang Y, Li X, Liu S, Cao S, Li X. Association between BRCA status and triple-negative breast cancer: A meta-analysis. Front Pharmacol. 2018;9:909. doi: 10.3389/fphar.2018.00909. - DOI - PMC - PubMed